Disparities in smoking and cessation status among cancer survivors and non-cancer individuals: a population-based study from National Health and Nutrition Examination Survey

Tseng, Tung-Sung; Lin, Hui‐Yi; Martin, Michelle Y.; Chen, Ted; Partridge, Edward E.

doi:10.1007/s11764-010-0127-9

Cited by 44 publications

(72 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other studies (10,11), this cross-sectional sample of survivors 9 years after diagnosis documented a lower smoking prevalence of 9.3%. A plausible explanation is mortality from cancer (particularly lung cancer, which has a low survival rate) in the 9 years since being diagnosed.…”

Section: Discussioncontrasting

confidence: 84%

“…Similar to prior studies (8)(9)(10), current smokers in the sample were of younger age compared with never and former smokers. Lower household income among survivors was also associated with increased odds of being a current smoker.…”

Section: Discussionsupporting

confidence: 82%

“…Yet a significant proportion of cancer survivors continue to smoke tobacco post-diagnosis (3)(4)(5)(6)(7). Population-based, cross-sectional surveys estimate that between 15% and 18% of cancer survivors currently smoke (8)(9)(10)(11), but prevalence varies by type of cancer diagnosis (9,10) and is higher among younger survivors (8,10) and those diagnosed with smokingrelated cancers (11). There is a lack of information on smoking prevalence and cessation interventions for survivors many years after diagnosis, however.…”

Section: Prevalence and Patterns Of Smoking In Survivorsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis

Westmaas

Alcaraz

Berg

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Smoking is detrimental to recovery and survival from cancer, but many cancer survivors continue to smoke. Information is lacking on smoking patterns of survivors many years after diagnosis and correlates of smoking status and patterns, likelihood of quitting, and intentions to quit.Methods: Cross-sectional analyses were conducted among survivors of 10 cancers recruited by stratified random sampling from cancer registries in a nationwide, longitudinal, quality-of-life study (n ¼ 2,938).Results: Approximately 9 years after diagnosis, 9.3% of all survivors were current (past 30-day) smokers. Smoking prevalence was highest among survivors of bladder (17.2%), lung (14.9%), and ovarian (11.6%) cancers. Most current smokers (83%) smoked daily, averaging 14.7 cigarettes per day (cpd). Forty percent of daily smokers smoked more than 15 cpd. Nondaily smokers smoked a mean of 10.9 days in the last 30 days and averaged 5.7 cpd on smoking days. Current smoking was associated with younger age, lower education and income, and greater alcohol consumption. Quitting after diagnosis was associated with having a smoking-related cancer. Roughly, a third of current smokers intended to quit, 40% within the next month. The odds of intending to quit were lower if survivors were married, older, or smoked more.Conclusions: This population-based study indicated that smoking can persist long after initial diagnosis and at high levels and identified characteristics associated with quitting and intentions to quit.Impact: Findings can be used to identify survivors most at risk for continued smoking and to inform tailoring of cessation treatments for survivors. Cancer Epidemiol Biomarkers Prev; 23(9); 1783-92. Ó2014 AACR.

show abstract

Section: Discussioncontrasting

confidence: 84%

Section: Discussionsupporting

confidence: 82%

Section: Prevalence and Patterns Of Smoking In Survivorsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis

Westmaas

Alcaraz

Berg

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…We analyzed quit status for any duration and repeated the analysis for former smokers with prolonged abstinence of at least one year (Hughes et al, 2003). All logistic regression analyses controlled for gender, age, poverty status, education level, and marital status because epidemiological studies have found associations with cigarette smoking status (Centers for Disease Control and Prevention, 2009a;Tseng, Lin, Martin, Chen, & Partridge, 2010).…”

Section: Analysis Strategymentioning

confidence: 99%

A Population-Based Examination of Cigarette Smoking and Mental Illness in Black Americans

Hickman

Delucchi

Prochaska

2010

Nicotine & Tobacco Research

View full text Add to dashboard Cite

“…Studies utilizing national datasets have shown that approximately 1 in 10 cancer survivors smoke [27-29]. Currently, tobacco treatment is not well-integrated into cancer care.…”

Section: Introductionmentioning

confidence: 99%

Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial

Park

Ostroff

Perez

et al. 2016

Contemporary Clinical Trials

View full text Add to dashboard Cite

Background Despite the well-established risks of persistent smoking, 10-30% of cancer patients continue to smoke after diagnosis. Evidence based tobacco treatment has yet to be integrated into routine oncology care. This paper describes the protocol, manualized treatment, evaluation plan, and overall study design of comparing the effectiveness and cost of two treatments across two major cancer centers. Methods/Design A two-arm, two-site randomized controlled comparative effectiveness trial is testing the hypothesis that an Intensive Treatment (IT) intervention is more effective than a Standard Treatment (ST) intervention in helping recently diagnosed cancer patients quit smoking. Both interventions include 4 weekly counseling sessions and FDA-approved smoking cessation medication advice. The IT includes an additional 4 biweekly and 3 monthly booster sessions as well as dispensal of the recommended FDA-approved smoking cessation medication at no cost. The trial is enrolling patients with suspected or newly diagnosed cancer who have smoked a cigarette in the past 30 days. Participants are randomly assigned to receive the ST or IT condition. Tobacco cessation outcomes are assessed at 3 and 6 months. The primary study outcome is 7-day point prevalence biochemically-validated tobacco abstinence. Secondary study outcomes include the incremental cost-effectiveness of the IT vs. ST. Discussion This trial will answer key questions about delivering tobacco treatment interventions to newly diagnosed cancer patients. If found to be efficacious and cost-effective, this treatment will serve as a model to be integrated into oncology care settings nation-wide, as we strive to improve treatment outcomes and quality of life for cancer patients.

show abstract

Disparities in smoking and cessation status among cancer survivors and non-cancer individuals: a population-based study from National Health and Nutrition Examination Survey

Cited by 44 publications

References 29 publications

Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis

Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis

A Population-Based Examination of Cigarette Smoking and Mental Illness in Black Americans

Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial

Contact Info

Product

Resources

About